Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.
Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results